Answers are grounded in this paper and cite their sources.
Single-center study reveals reduced chemotherapy wastage in hospital pharmacy operations, highlighting the cost-saving potential of robotic compounding.
This study aimed to evaluate the drug cost-saving effects of drug vial optimization (DVO) using an anticancer drug compounding robot in a single institution. Robotic preparations, drug costs, and wastage were evaluated from April to July 2022. Cost-saving simulations were conducted assuming same-day or 7-day DVO. From September to December 2022, DVO was performed for paclitaxel, carboplatin, and etoposide, and actual cost savings were evaluated. During the initial period, 2613 doses (42.0%) were prepared by the robot, with a wastage rate of 2.7%. The simulated cost savings were approximately ¥2.8 million (same-day) and ¥7.49 million (7-days). After the introduction of DVO, 291 vials were saved, equivalent to ¥790000. In conclusion, DVO using an anticancer drug compounding robot can reduce anticancer drug wastage and may contribute to drug cost savings in clinical practice.
No takes yet. Share an insight, caveat, or question.
Sato et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: